Insulet begins patient enrolment for EVOLVE trial

Insulet has commenced patient enrolment in its pivotal EVOLVE study, evaluating a fully closed-loop AID system for adults with T2D. Insulet anticipates a 510(k) submission for its fully closed-loop AID system in 2027 and market launch in 2028. The trial will enrol up to 350 adults, aged 18-75, with type 2 diabetes. Credit: Andrzej Rostek / Shutterstock.com. Insulet has commenced patient enrolment in its pivotal EVOLVE study, evaluating a fully closed-loop automated insulin delivery (AID) system for adults with type 2 diabetes (T2D). The system eliminates the need for user-initiated bolusing and mealtime announcements, streamlining diabetes management in a range…

Source: Medical Device Network